Would you consider adding Enasidinib to frontline combination therapy with HMA and Venetoclax in a patient with newly diagnosed AML with IDH2 mutation that is >75 or unfit for standard induction therapy?
Answer from: Medical Oncologist at Academic Institution
This question raises an important treatment consideration, but I would probably not use triple agents at this stage given lack of maturity of clinical trials. Venetoclax has been quite effective in those who have IDH1 and IDH2 mutations (Chan SM et al Nat Med 2015; 21:178), so I would probably...
Comments
Medical Oncologist at University of California Davis Comprehensive Cancer Center I agree with @Jane Liesveld. Currently, I would be...
I agree with @Jane Liesveld. Currently, I would be...